University/Organization: University of Nebraska Medical Center
Country: India
Dr. Rajesh R Wakaskar has received his Ph.D. in Pharmaceutical Sciences from the University of Nebraska Medical Center in 2015. Currently, he is working as a Formulation Scientist at Insys Therapeutics. His current profile encompasses providing support in Pre-formulation and Formulation Development, Clinical supplies manufacture, API and Drug Product Stability and writing CMC sections of the IND and NDA that are submitted to the FDA for review and approval of pharmaceutical products. His graduate project involved the development of shell cross-linked polymeric micelles (nanocarriers) for the delivery of poorly water soluble anti-cancer agents such as Combretastatin A4 (CA4) to improve the existing solubility, efficacy, bioavailability of this drug, and subsequently, overall therapy of breast cancer. Based on his research, he has been awarded several honors in various podia and poster presentations at various conferences and is an author of high impact research articles in reputed journals. Currently, he’s serving as an expert reviewer for various Journals such as Journal of Drug Delivery, Science and Technology, Clinical Pharmacology & Biopharmaceutics Journal, Cardiovascular Pharmacology, Advances in Pharmacoepidemiology & Drug Safety, Journal of Applied Pharmacy, Pharmaceutical Sciences, Journal of Molecular Biomarkers and Diagnosis (to name a few).
Rajesh Wakaskar research interests includes Developing and improving upon the existing concepts of drug delivery; Providing specific insights into the development of nanotechnology, both as a therapeutic and diagnostic tool; Aiding the successful transition of bench-scale science to clinical development of therapeutic products
Scientia Ricerca is licensed and content of this site is available under a Creative Commons Attribution 4.0 International License.